Johnson & Johnson
Latest statistics and disclosures from Johnson & Johnson's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LEGN, CVRX, PTGX, MGTX, XNCR, and represent 72.30% of Johnson & Johnson's stock portfolio.
- Added to shares of these 2 stocks: NMRA (+$13M), NBTX (+$8.4M).
- Started 2 new stock positions in NMRA, NBTX.
- Johnson & Johnson was a net buyer of stock by $21M.
- Johnson & Johnson has $272M in assets under management (AUM), dropping by -15.71%.
- Central Index Key (CIK): 0000200406
Tip: Access up to 7 years of quarterly data
Positions held by Johnson & Johnson consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Johnson & Johnson
Johnson & Johnson holds 24 positions in its portfolio as reported in the September 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Legend Biotech Corporation Ads (LEGN) | 20.2 | $55M | 815k | 67.17 |
|
|
| CVRX (CVRX) | 19.5 | $53M | 3.5M | 15.17 |
|
|
| Protagonist Therapeutics (PTGX) | 15.0 | $41M | 2.4M | 16.68 |
|
|
| Meiragtx Holdings (MGTX) | 12.0 | $33M | 6.6M | 4.91 |
|
|
| Xencor (XNCR) | 5.6 | $15M | 748k | 20.15 |
|
|
| Neumora Therapeutics (NMRA) | 4.7 | $13M | NEW | 912k | 14.11 |
|
| Procept Biorobotics Corp (PRCT) | 4.3 | $12M | 358k | 32.81 |
|
|
| Fusion Pharmaceuticals (FUSN) | 3.5 | $9.5M | 3.7M | 2.60 |
|
|
| Nanobiotix Sponsored Ads (NBTX) | 3.1 | $8.4M | NEW | 960k | 8.75 |
|
| Fate Therapeutics (FATE) | 2.6 | $7.2M | 3.4M | 2.12 |
|
|
| Point Biopharma Global | 2.5 | $6.7M | 1.0M | 6.67 |
|
|
| Arrowhead Pharmaceuticals (ARWR) | 2.5 | $6.7M | 248k | 26.87 |
|
|
| Aldeyra Therapeutics (ALDX) | 1.0 | $2.6M | 395k | 6.68 |
|
|
| Cue Health (HLTH) | 0.9 | $2.5M | 5.5M | 0.44 |
|
|
| Vor Biopharma (VOR) | 0.8 | $2.3M | 1.1M | 2.12 |
|
|
| Nano-X Imaging Ord Shs (NNOX) | 0.8 | $2.1M | 318k | 6.56 |
|
|
| Adicet Bio (ACET) | 0.4 | $999k | 729k | 1.37 |
|
|
| Chardan Healthcare Acqu- Ord (PHGE) | 0.3 | $751k | 2.1M | 0.35 |
|
|
| Somalogic | 0.2 | $672k | 281k | 2.39 |
|
|
| Clearside Biomedical (CLSD) | 0.1 | $148k | 170k | 0.87 |
|
|
| Apollomics Cl A Shs (APLM) | 0.0 | $50k | 13k | 3.75 |
|
|
| Senseonics Hldgs (SENS) | 0.0 | $33k | 55k | 0.60 |
|
|
| Catalyst Biosciences | 0.0 | $32k | 67k | 0.48 |
|
|
| Tracon Pharmaceuticals (TCON) | 0.0 | $15k | 84k | 0.18 |
|
Past Filings by Johnson & Johnson
SEC 13F filings are viewable for Johnson & Johnson going back to 2021
- Johnson & Johnson 2023 Q3 filed Nov. 9, 2023
- Johnson & Johnson 2023 Q2 filed Aug. 2, 2023
- Johnson & Johnson 2023 Q1 filed May 11, 2023
- Johnson & Johnson 2022 Q4 filed Feb. 9, 2023
- Johnson & Johnson 2022 Q3 filed Nov. 10, 2022
- Johnson & Johnson 2022 Q2 filed Aug. 10, 2022
- Johnson & Johnson 2022 Q1 filed May 9, 2022
- Johnson & Johnson 2021 Q4 filed Feb. 14, 2022
- Johnson & Johnson 2021 Q3 restated filed Nov. 16, 2021
- Johnson & Johnson 2021 Q3 filed Nov. 12, 2021